Share Prices & Company Research

Market News

11 Feb 2021 | 08:33

Eden Research losses widen as revenues slip amid Covid-19

(Sharecast News) - Biopesticides group Eden Research warned on Thursday that full-year losses were set to have widened in 2020 due to a decline in revenues amid the Covid-19 pandemic. Eden said revenue for the year was expected to be approximately £1.6m, down from £2.0m in 2019, with a loss before tax and a statutory operating loss of approximately £2.6m, nearly double the £1.4m loss recorded in the prior year.

The AIM-listed group stated product sales during the period were affected by the impact of the global pandemic on the hospitality industry which, in turn, affected wine grape production methods and the widespread use of crop protection products.

Eden added that a number of product approvals which had been expected in the year, which would have resulted in product sales, were also delayed.

Chief executive Sean Smith said: "It has been an unprecedented year for businesses across the globe, and Eden has not been immune to the disruption caused by the Covid-19 pandemic.

"However, we are proud of the resilience we have demonstrated against this exceptional backdrop and the continued progress we have made in advancing our strategy and positioning Eden for growth in the rapidly growing biopesticides market.

As of 1310 GMT, Eden shares were down 7.58% at 13.77p.
Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new account or transferring your account from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
Continuing our Personal Service: View our Latest COVID-19 Update: 30th April 2021
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.